Research programme : antibody drug conjugates - OBI Pharma

Drug Profile

Research programme : antibody drug conjugates - OBI Pharma

Alternative Names: OBI-999

Latest Information Update: 14 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OBI Pharma
  • Class Antibodies; Antineoplastics; Drug conjugates
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 11 Jul 2017 Preclinical trials in Cancer in Taiwan (Parenteral), before July 2017
  • 11 Jul 2017 Abzena in-licenses ThioBridge antibody drug conjugate linker technology from Abzena
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top